Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study-Reference-Cited by-同舟云学术

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Published:2019-08 Issue:8 Volume:20 Page:1083-1097
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Long Georgina V,Dummer Reinhard,Hamid Omid,Gajewski Thomas F,Caglevic Christian,Dalle Stephane,Arance Ana,Carlino Matteo S,Grob Jean-Jacques,Kim Tae Min,Demidov Lev,Robert Caroline,Larkin James,Anderson James R,Maleski Janet,Jones Mark,Diede Scott J,Mitchell Tara C

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med,2015

2. Pembrolizumab versus ipilimumab in advanced melanoma;Robert;N Engl J Med,2015

3. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

5. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial;Hodi;Lancet Oncol,2018

Cited by 660 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloid-derived suppressor cells in cancer: Current knowledge and future perspectives;International Immunopharmacology;2024-12

2. Heme-based dioxygenases: Structure, function and dynamics;Journal of Inorganic Biochemistry;2024-12

3. Overview of the role of purinergic signaling and insights into its role in cancer therapy;Pharmacology & Therapeutics;2024-10

4. IDO1 inhibitors are synergistic with CXCL10 agonists in inhibiting colon cancer growth;Biomedicine & Pharmacotherapy;2024-10

5. Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape;Frontiers in Immunology;2024-09-13